What is Endra Life Sciences Inc's earnings per share (EPS)?

Endra Life Sciences Inc (NDRA) reported diluted earnings per share of -$8.93 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Endra Life Sciences Inc Financials

NDRA

FY2025 annual

Revenue Not reported for FY2025

Net Income -$7.0M +38.9% YoY

EPS (Diluted) -$8.93 YoY not available

Free Cash Flow -$5.2M +29.9% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

This page shows Endra Life Sciences Inc (NDRA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NDRA FY2025 2026-05-15

ENDRA’s cost-cutting has nearly halved annual cash burn, yet it remains an externally funded development business.

In the latest year, financing inflow of $5.7M only barely covered operating cash burn of -$5.2M. That is why cash finished at $762K and the current ratio fell to 1.3x even though the income statement looked less negative than a year earlier; the business is leaner, but not yet self-funding.

The latest improvement came from a smaller cost base, not evidence of a scaling revenue engine: SG&A dropped from $7.1M to $3.7M. R&D spending also stepped down, and operating cash flow remained close to net loss, so the narrower deficit mostly reflects real cash savings rather than accounting effects.

With $1.6M of liabilities against $2.3M of equity, the balance sheet is not dominated by debt. But liquidity is much tighter than solvency: current assets only modestly cover current liabilities, and inventory no longer provides a working-capital buffer, leaving access to fresh capital as the immediate operating constraint.

Financial Health Signals

Financial health score not available

Endra Life Sciences Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

Endra Life Sciences Inc passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

Endra Life Sciences Inc reported a net loss of $7.0M while operations used $5.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$5.7M

YoY+46.9%

Endra Life Sciences Inc's EBITDA was -$5.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 46.9% from the prior year.

Net Income

-$7.0M

YoY+38.9%

Endra Life Sciences Inc reported -$7.0M in net income in fiscal year 2025. This represents an increase of 38.9% from the prior year.

EPS (Diluted)

-$8.93

Endra Life Sciences Inc earned -$8.93 per diluted share (EPS) in fiscal year 2025.

Revenue

Not reported for fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

-$5.2M

YoY+29.9%

Endra Life Sciences Inc recorded an outflow of $5.2M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 29.9% from the prior year.

Cash & Debt

$762K

YoY-76.4%

5Y CAGR-36.2%

Endra Life Sciences Inc held $762K in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

Endra Life Sciences Inc had 1M shares outstanding in fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity

-310.9%

YoY+138.5pp

5Y CAGR-147.4pp

Endra Life Sciences Inc's ROE was -310.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 138.5 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not reported for fiscal year 2025.

Net Margin

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

$1.8M

YoY-42.0%

5Y CAGR-20.7%

Endra Life Sciences Inc invested $1.8M in research and development in fiscal year 2025. This represents a decrease of 42.0% from the prior year.

Capital Expenditures

$17K

YoY+8.0%

5Y CAGR-25.5%

Endra Life Sciences Inc invested $17K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 8.0% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

NDRA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

NDRA quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$6K-98.2%	$352K-31.8%	$516K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0-100.0%	$173K	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$6K-96.5%	$179K-36.1%	$280K
R&D Expenses	N/A	$1.8M-42.0%	$3.2M-36.2%	$5.0M-23.7%	$6.6M+19.5%	$5.5M-7.4%	$5.9M-10.0%	$6.6M+39.2%	$4.7M+144.6%	$1.9M+289.8%	$495K
SG&A Expenses	N/A	$3.7M-47.2%	$7.1M+50.2%	$4.7M-9.2%	$5.2M+4.7%	$4.9M-1.2%	$5.0M+29.7%	$3.9M+2.8%	$3.8M+36.4%	$2.8M+78.4%	$1.5M
Operating Income	N/A	-$5.8M+46.7%	-$10.8M-2.8%	-$10.5M+20.0%	-$13.2M-14.4%	-$11.5M0.0%	-$11.5M-6.1%	-$10.8M-20.2%	-$9.0M-95.0%	-$4.6M-158.2%	-$1.8M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$43K-40.8%	$72K
Income Tax	N/A	N/A	$0	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	N/A	-$7.0M+38.9%	-$11.5M-14.4%	-$10.1M+23.7%	-$13.2M-17.3%	-$11.2M+4.2%	-$11.7M+11.9%	-$13.3M-35.8%	-$9.8M-82.2%	-$5.4M	N/A
EPS (Diluted)	-$6.38	-$8.93	-$56.94	-$2766.85	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
R&D Expenses	$234K-69.9%	$776K	N/A	$432K+13.4%	$381K-27.9%	$529K	N/A	$794K
SG&A Expenses	$1.2M-10.7%	$1.4M	N/A	$893K+4.9%	$851K-2.3%	$872K	N/A	$631K
Operating Income	-$1.5M+31.8%	-$2.2M	N/A	-$1.4M-5.4%	-$1.3M+11.4%	-$1.5M	N/A	-$1.5M
Income Tax	N/A	N/A	N/A	N/A	$0	$0	N/A	$0
Net Income	$160K+112.2%	-$1.3M	N/A	-$1.6M-30.2%	-$1.2M-18.3%	-$1.0M	N/A	-$2.4M
EPS (Diluted)	$0.06	-$1.09+66.5%	-$3.25-54.8%	-$2.10-22.8%	-$1.71+8.1%	-$1.86-107.4%	$25.20+364.2%	-$9.54

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.

NDRA Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

NDRA quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16
Total Assets	$3.9M-13.4%	$4.5M-34.1%	$6.8M-27.2%	$9.3M-28.0%	$12.9M+46.9%	$8.8M+22.1%	$7.2M-0.6%	$7.2M+17.9%	$6.1M+1147.8%	$491K
Current Assets	$968K-71.8%	$3.4M+13.2%	$3.0M-43.6%	$5.4M-55.5%	$12.1M+47.4%	$8.2M+25.6%	$6.5M-6.0%	$6.9M+18.1%	$5.9M+2907.3%	$196K
Cash & Equivalents	$762K-76.4%	$3.2M+14.0%	$2.8M-42.0%	$4.9M-48.3%	$9.5M+30.9%	$7.2M+17.1%	$6.2M-4.6%	$6.5M+15.5%	$5.6M+3764.6%	$145K
Inventory	$0	$0-100.0%	$2.6M-0.8%	$2.6M+105.9%	$1.3M+117.9%	$590K+419.8%	$113K+90.8%	$59K-69.0%	$192K+377.9%	$40K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$7K	$0
Total Liabilities	$1.6M-15.8%	$1.9M+72.8%	$1.1M-47.1%	$2.1M-1.0%	$2.1M+31.0%	$1.6M-33.9%	$2.4M+147.9%	$975K+14.9%	$848K-38.7%	$1.4M
Current Liabilities	$751K+24.1%	$605K-33.0%	$903K-47.0%	$1.7M+10.4%	$1.5M+56.5%	$987K-52.4%	$2.1M+112.7%	$975K+14.9%	$848K-38.7%	$1.4M
Long-Term Debt	N/A	$0	$0	$0-100.0%	$547K	N/A	N/A	N/A	N/A	N/A
Total Equity	$2.3M-11.7%	$2.6M-54.8%	$5.7M-21.5%	$7.2M-33.2%	$10.8M+50.4%	$7.2M+50.6%	$4.8M-23.8%	$6.2M+18.4%	$5.3M+690.3%	-$894K
Retained Earnings	-$110.5M-6.8%	-$103.4M-12.5%	-$91.9M-12.3%	-$81.9M-19.2%	-$68.7M-19.8%	-$57.3M-26.8%	-$45.2M-63.3%	-$27.7M-54.7%	-$17.9M-43.0%	-$12.5M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$7.9M+131.0%	$3.4M-10.8%	$3.9M+96.2%	$2.0M-30.0%	$2.8M-11.4%	$3.2M-28.8%	$4.5M-46.9%	$8.4M
Current Assets	$5.6M+941.1%	$537K-44.6%	$968K-7.7%	$1.0M-43.4%	$1.9M-15.0%	$2.2M-36.5%	$3.4M-30.8%	$5.0M
Cash & Equivalents	$1.7M+388.1%	$356K-53.2%	$762K-4.0%	$794K-56.1%	$1.8M-12.4%	$2.1M-36.1%	$3.2M-31.9%	$4.7M
Inventory	N/A	N/A	$0	$0	$0	$0	$0-100.0%	$2.7M
Total Liabilities	$1.6M-1.1%	$1.7M+3.6%	$1.6M-11.1%	$1.8M+34.3%	$1.3M-5.9%	$1.4M-25.1%	$1.9M+6.6%	$1.8M
Current Liabilities	$787K-5.8%	$835K+11.3%	$751K-6.2%	$800K+38.8%	$577K+1.9%	$566K-6.5%	$605K-25.7%	$814K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	$0	N/A
Total Equity	$6.3M+253.1%	$1.8M-20.9%	$2.3M+1218.8%	$171K-88.4%	$1.5M-16.0%	$1.8M-31.5%	$2.6M-61.2%	$6.6M
Retained Earnings	-$111.6M+0.1%	-$111.8M-1.2%	-$110.5M-3.0%	-$107.3M-1.5%	-$105.7M-1.2%	-$104.5M-1.0%	-$103.4M-4.2%	-$99.3M

Not reported in any period shown, so not listed: Accounts Receivable, Goodwill.

NDRA Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

NDRA quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16
Operating Cash Flow	-$4.8M	-$5.2M+30.0%	-$7.4M+22.5%	-$9.5M+25.2%	-$12.8M-14.8%	-$11.1M-3.5%	-$10.7M-25.1%	-$8.6M-11.5%	-$7.7M-133.3%	-$3.3M-150.9%	-$1.3M
Capital Expenditures	N/A	$17K+8.0%	$16K-52.8%	$34K-83.3%	$203K+350.2%	$45K-40.3%	$75K+72.8%	$44K-56.4%	$100K+1171.9%	$8K	N/A
Free Cash Flow	N/A	-$5.2M+29.9%	-$7.4M+22.6%	-$9.6M+26.1%	-$13.0M-16.2%	-$11.2M-3.2%	-$10.8M-25.4%	-$8.6M-10.6%	-$7.8M-135.8%	-$3.3M	N/A
Investing Cash Flow	-$333K	-$3.0M-23479.9%	-$13K+48.2%	-$25K+87.8%	-$203K-350.2%	-$45K+40.3%	-$75K-72.8%	-$44K+56.4%	-$100K-1171.9%	-$8K	$0
Financing Cash Flow	$8.9M	$5.7M-26.6%	$7.8M+3.9%	$7.5M-10.5%	$8.4M-37.3%	$13.4M+12.9%	$11.9M+42.5%	$8.3M-3.9%	$8.7M-1.1%	$8.8M+508.1%	$1.4M
Dividends Paid	N/A	N/A	N/A	N/A	$0-100.0%	$121K-69.4%	$396K-90.6%	$4.2M	$0	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$928K+17.2%	-$1.1M+30.5%	-$1.6M-38.5%	-$1.2M-4.5%	-$1.1M+13.9%	-$1.3M+14.7%	-$1.5M+8.5%	-$1.7M
Capital Expenditures	N/A	N/A	$0	$0	$0-100.0%	$17K	$0	$0
Free Cash Flow	N/A	N/A	-$1.6M-38.5%	-$1.2M-4.5%	-$1.1M+15.0%	-$1.3M+13.5%	-$1.5M+8.5%	-$1.7M
Investing Cash Flow	$2.2M+392.7%	$450K+115.0%	-$3.0M	$0	$0+100.0%	-$17K	$0	$0
Financing Cash Flow	$3.9M+1376.4%	$264K-94.2%	$4.6M+2964.3%	$149K-82.6%	$857K+488.1%	$146K	$0-100.0%	$2K

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

NDRA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

NDRA quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	100.0%+49.1pp	50.9%-3.4pp	54.3%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-146080.5%	-1315.6%	-347.5%
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-158669.6%	-1529.2%	N/A
Return on Equity	-310.9%+138.5pp	-449.5%-271.7pp	-177.8%+5.2pp	-182.9%-78.8pp	-104.1%+59.4pp	-163.5%+116.0pp	-279.5%-122.7pp	-156.8%-54.9pp	-101.9%	N/A
Return on Assets	-182.3%+76.1pp	-258.5%-109.5pp	-149.0%-6.8pp	-142.1%-54.9pp	-87.2%+46.5pp	-133.8%+51.6pp	-185.4%-49.8pp	-135.6%-47.8pp	-87.8%	N/A
Current Ratio	1.29-4.4x	5.67+2.3x	3.36+0.2x	3.16-4.7x	7.83-0.5x	8.32+5.2x	3.15-4.0x	7.13+0.2x	6.93+6.8x	0.14
Debt-to-Equity	0.71+0.7x	0.000.0x	0.000.0x	0.00-0.1x	0.05-0.2x	0.22-0.3x	0.51+0.4x	0.160.0x	0.16	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-126376.4%	-941.0%	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Return on Equity	2.5%+75.9pp	-73.4%	N/A	-931.2%-848.0pp	-83.2%-24.1pp	-59.1%	N/A	-35.6%
Return on Assets	2.0%+40.2pp	-38.1%	N/A	-81.3%-37.6pp	-43.7%-11.0pp	-32.7%	N/A	-28.1%
Current Ratio	7.10+6.5x	0.64-0.6x	1.290.0x	1.31-1.9x	3.21-0.6x	3.85-1.8x	5.67-0.4x	6.10
Debt-to-Equity	0.26-0.7x	0.92+0.2x	0.71-9.8x	10.46+9.6x	0.91+0.1x	0.81+0.8x	0.00-0.3x	0.27

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Check Cap CHEK

$9.4M

Applied Dna Scie APDN

$7.3M

bioAffinity Tech BIAF

$3.0M

Mainz Biomed NV MYNZ

$10.6M

XWELL Inc XWEL

$8.5M

Where Endra Life Sciences Inc Ranks

Frequently Asked Questions

Is Endra Life Sciences Inc profitable?

No, Endra Life Sciences Inc (NDRA) reported a net income of -$7.0M in fiscal year 2025.

What is Endra Life Sciences Inc's EBITDA?

Endra Life Sciences Inc (NDRA) had EBITDA of -$5.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Endra Life Sciences Inc's return on equity (ROE)?

Endra Life Sciences Inc (NDRA) has a return on equity of -310.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Endra Life Sciences Inc's free cash flow?

Endra Life Sciences Inc (NDRA) recorded an outflow of $5.2M in free cash flow during fiscal year 2025. This represents a 29.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Endra Life Sciences Inc's operating cash flow?

Endra Life Sciences Inc (NDRA) recorded an outflow of $5.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Endra Life Sciences Inc's total assets?

Endra Life Sciences Inc (NDRA) had $3.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Endra Life Sciences Inc's capital expenditures?

Endra Life Sciences Inc (NDRA) invested $17K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Endra Life Sciences Inc spend on research and development?

Endra Life Sciences Inc (NDRA) invested $1.8M in research and development during fiscal year 2025.

How many shares does Endra Life Sciences Inc have outstanding?

Endra Life Sciences Inc (NDRA) had 1M shares outstanding as of fiscal year 2025.

What is Endra Life Sciences Inc's current ratio?

Endra Life Sciences Inc (NDRA) had a current ratio of 1.29 as of fiscal year 2025, which is considered adequate.

What is Endra Life Sciences Inc's debt-to-equity ratio?

Endra Life Sciences Inc (NDRA) had a debt-to-equity ratio of 0.71 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Endra Life Sciences Inc's return on assets (ROA)?

Endra Life Sciences Inc (NDRA) had a return on assets of -182.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Endra Life Sciences Inc's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Endra Life Sciences Inc (NDRA) held $762K in cash, cash equivalents and investments, and reported an operating cash outflow of $5.2M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Endra Life Sciences Inc's Piotroski F-Score?

Endra Life Sciences Inc (NDRA) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Endra Life Sciences Inc's earnings high quality?

Endra Life Sciences Inc (NDRA) reported a net loss of $7.0M while operations used $5.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.